Highlights GLP-1 drugs have come to be thought of as “wonder drugs,” yet the mechanisms behind their many new health benefits have remained unclear New research from the Salk Institute reveals the mec...

YouTube video by Sector Alpha Gaming

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health. In addition to these surprising bonus benefits is the ability of GLP-1 drugs to improve pancreatic beta cell health. But how, exactly, are they doing that? Salk Institute researchers are burrowing down into the mechanistic details behind how GLP-1 drugs promote viability and stress resistance in pancreatic beta cells. Since cellular performance adaptations arise from gene expression changes, the team screened for regulatory proteins that can flip "on" advantageous gene programs during prolonged GLP-1 use. They identified a protein called Med14-part of a larger protein complex called Mediator-that was enabling the GLP-1-dependent changes in gene expression that lead to pancreatic health benefits. The study was published in Proceedings of the National Academy of Sciences on March 4, 2026, and was funded by federal research grants from the National Institutes of Health and private philanthropy. The broad salutary effects of GLP-1 drugs in diabetes, cardiovascular disease, and obesity have sparked a wave of exciting scientific research at the mechanistic level. We're left wondering, 'How are GLP-1s causing these...

We and others previously found that hRSV NS1 associates with Mediator complex, including MED1, MED14, and MED25 subunits17,19,20,29. Of these subunits, proteins from multiple viruses hijack MED25 to enhance expression of viral genes28. MED25 contains two domains: an N-terminal von...

Key Highlights • A new study reveals that a specific protein modification, the phosphorylation of Med14, is crucial for how cells respond to diabetes drugs like Ozempic. This finding helps explain how these medications work at a molecular level to improve insulin secretion and protect insulin-producing cells. Source → • Researchers have discovered that a receptor called GPR183 allows immune cells called monocytes to sense chemical signals from lung tissue, guiding them to become specialized lung macrophages.

GLP-1s are building a reputation as "wonder drugs." First characterized for their ability to improve insulin release and treat diabetes, the drugs were later found to promote weight loss and improve cardiovascular health.